منابع مشابه
Has the time come to abandon efavirenz for first-line antiretroviral therapy?
Efavirenz has been recommended as a preferred third agent together with two nucleos(t)ides for first-line combination antiretroviral therapy (ART) for >15 years. The availability of efavirenz in a fixed-dose combination makes it very attractive. However, because of (i) adverse events associated with efavirenz, (ii) a poorer overall efficacy of efavirenz compared with newer antiretrovirals, (iii...
متن کاملQuality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
OBJECTIVE To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL). DESIGN A sub-study of the 2NN study, with antiretroviral-naive patients randomly allocated to NVP (once or twice daily), EFV or NVP+EFV, in addition to stavudine and lamivudine. METHODS...
متن کاملPeer review: still king in the digital age
The article presents one of the main fi ndings of an international study of 4,000 academic researchers that examined how trustworthiness is determined in the digital environment when it comes to scholarly reading, citing, and publishing. The study shows that peer review is still the most trustworthy characteristic of all. There is, though, a common perception that open access journals are not p...
متن کاملNeurology: still in first gear.
Editor – Jones et al (Clin Med October 2013 pp 460–4) provide a revealing analysis of the distribution of patients with diabetes and kidney disease across the health service. They show that applying traditional referral guidelines which use arbitrary estimated glomerular fi ltration rate (eGFR) criteria leads to patients who should be managed in primary care remaining under nephrologists and vi...
متن کاملIs imatinib still an acceptable first-line treatment for CML in chronic phase?
The introduction of the tyrosine kinase inhibitor (TKI) imatinib (Gleevec) into clinical practice resulted in a very dramatic prolongation of survival for most, but not all, patients with chronic myeloid leukemia in chronic phase (CML-CP). A leukemia with a median survival of about 5 years was transformed into one for which the survival in many cases promises to be comparable to that of normal ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Drug Metabolism & Toxicology
سال: 2008
ISSN: 1742-5255,1744-7607
DOI: 10.1517/17425255.4.7.965